Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Female Urinary Incontinence Products Market $950 Million by 2027

The global market for female urinary incontinence products is expected to exceed $950 million by 2027, expanding at a CAGR of 3.8% over the forecast period, driven by unmet medical needs, and increasing preference for minimally invasive surgical procedures.

  • Other factors driving the growth of female continence care market include increased number of ageing, diabetic and obese population, and rising prevalence of spinal cord injury and spina bifida.
  • Research has revealed overlapping potential causes of incontinence, including dysfunction of the detrusor muscle or muscles of the pelvic floor, dysfunction of the neural controls of storage and voiding, and perturbation of the local environment within the bladder. 
Global Female Urinary Incontinence Products Market

Urinary incontinence affects more than 300 million people and its prevalence is increasing worldwide. With the increasing number of elderly people in the developed countries the prevalence of SUI is growing.

  • Worldwide median prevalence of female urinary incontinence is 27.6%, divided in stress (50%), mixed (32%), and urge incontinence (14%). The  stress incontinence and urgency incontinence are so common that they often coexist, as a combination of symptoms termed mixed incontinence. Most women with urgency incontinence also receive a diagnosis of overactive bladder syndrome.
    • In women, the main UI risk factors are highly correlated to age, pregnancy, childbirth, menopause, hysterectomy, obesity, and other altered conditions.
  • It is estimated that, the number of women with urinary incontinence in the U.S. will increase by 55% until 2050, thus affecting one third of all women.
    • An estimated 85% of all patients with SUI are women and the prevalence of SUI in the U.S. ranges from 26% to 31%), with the highest incidence in women aged 40 to 60 years.
  • According the U.S. National Institute of Health (NIH), it is estimated that SUI affects 15 million women in the U.S. alone.
    • More than 300,000 incontinence procedures are performed annually in the U.S.
    • The American Urological Association (AUA) made recommendation on the surgical management of stress UI in women.

The global minimally invasive female urinary incontinence devices market research report provides market size ($million 2017 to 2027), market share analysis, growth trends and forecast (CAGR%, 2021 to 2027).

The global female urinary incontinence products market segmented by product (injectable urethral bulking agents, urethral sling systems, neuromodulation systems), incontinence type (stress incontinence, urge incontinence, mixed incontinence), end user (ambulatory surgical centers, gynecology clinics, hospitals) and geography.

Minimally invasive surgical procedures are often used to treat the most common type of incontinence, stress urinary incontinence (SUI).

  • No medications are approved by the U.S. Food and Drug Administration (FDA) for treatment of stress UI, the American College of Physicians recommends against systemic pharmacotherapy. Mechanical devices for stress UI management include vaginal inserts (cones, pessaries) and urethral plugs.
    • These devices frequently require intravaginal estrogen before use and are most often discontinued because of poor fit; however, they may be effective in patients with predictable, episodic symptoms (e.g., during exercise, pregnancy), in nonsurgical candidates, or in those awaiting surgery. 
  • The current treatment options for SUI include pelvic muscle therapy (Kegel exercise), medication, non-surgical medical devices including urinary bulking agents (UBAs) and invasive procedures such as slings and vaginal tapes and other surgical procedures.
    • Several surgical mesh implants have been withdrawn from the market for causing serious injuries.
  • Injectable urinary bulking agents composed of synthetic materials, bovine collagen, or autologous substances.
    • The main advantage of injectables is their easy out-patient procedure and their safety profile, even in very ill patients.
      • However, low success rates are also reported after the injection of the presently approved bulking agents, due to their application has been limited by placement, durability, antigenicity, and other compatibility issues.
  • Several FDA-approved UBA products have been developed and are commercially available, where key factors in determining the optimal product are biocompatibility, durability and absence of migration.
    • The first cross-linked bovine collagen UBA (Contigen, C. R. Bard) was discontinued in 2011.
    • Other UBAs include autologous fat injections, solid silicone particles (Macroplastique, Cogentix Medical), microspheres covered with pyrolytic carbon (Durasphere, Coloplast), calcium hydroxyapatite (Coaptite, Boston-Scientific), polyacrylamide hydrogel (Bulkamid, Contura A/S), and dextran/HA copolymer (Zuidex, Q-Med AB/Galderma).
      • The latest product development is PDMS-U, a silicone gel bulking agent that polymerizes in situ (Urolastic, Urogyn B. V.).
  • Urethral sling systems for SUI is considered as the preferred surgical intervention.
    • The gold-standard in the treatment of SUI today is still the use of minimally invasive tension-free vaginal tape (TVT). The retropubic suburethral sling has become the mainstay for surgical management of moderate to severe SUI.
  • Neuromodulation has been reported to be effective for the treatment of stress and urgency urinary incontinence.
    • It is a well-established treatment option for patients with non-neurogenic overactive bladder and urinary retention.
    • The cure and improvement rates of pelvic floor neuromodulation in urinary incontinence have improved over time.
    • Sacral nerve stimulation (SNS) is currently intended for the treatment of intractable urinary urge incontinence, non-obstructive urinary retention, and urgency/frequency syndrome in adults.
      • Pelvic floor electrical stimulation can be performed in a clinical setting or at home.
      • Electrical stimulation has also been employed in the treatment of UI, especially in Europe.

The global minimally invasive female urinary incontinence devices market research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA) and Rest of the World.

In addition, the global market for female urinary incontinence products report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major competitors operating in the global market for female urinary incontinence products and profiled in this report include Axonics Modulation Technologies, Inc., BlueWind Medical Ltd., Boston Scientific Corporation, Caldera Medical, Inc., Carbon Medical Technologies, Inc., CL Medical Ltd., Coloplast Corporation, Cousin Surgery SAS (Cousin Biotech S.A.S.), FemPulse Corporation, Johnson & Johnson (Ethicon, Inc.), Laborie Medical Technologies, Inc. (Cogentix Medical, Inc.), Medtronic plc, and Uro Medical Corporation (Micron Medical/StimGuard LLC).

  • Product
    • Injectable Urethral Bulking Agents for Stress Urinary Incontinence (SUI)
    • Urethral Sling Systems for SUI
    • Neuromodulation Systems to Treat Overactive Bladder (OAB)
  • Incontinence Type
    • Stress incontinence (SUI)
    • Urge incontinence (UUI)
    • Mixed incontinence (MUI)
  • End User
    • Ambulatory Surgical Centers (ASCs)
    • Gynecology Clinics
    • Hospitals
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Axonics Modulation Technologies, Inc.
    • BlueWind Medical Ltd.
    • Boston Scientific Corporation
    • Caldera Medical, Inc.
    • Carbon Medical Technologies, Inc.
    • CL Medical Ltd.
    • Coloplast Corporation
    • Cousin Surgery SAS (Cousin Biotech S.A.S.)
    • FemPulse Corporation
    • Johnson & Johnson (Ethicon, Inc.)
    • Laborie Medical Technologies, Inc. (Cogentix Medical, Inc.)
    • Medtronic plc
    • Uro Medical Corporation (Micron Medical/StimGuard LLC)

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/minimally-invasive-female-urinary-incontinence-devices-market/

Related publications:



    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com